NCT00817414

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	LCI699-matching placebo	LCI699-matching placebo oral capsules
DRUG	LCI699	LCI699 oral capsules

Timeline

• Start date: 2009-01-14
• Primary completion: 2009-08-12
• Completion: 2009-08-12
• First posted: 2009-01-06
• Last updated: 2021-06-02
• Results posted: 2021-06-02

Locations

11 sites across 2 countries: United States, Iceland

Regulatory

• FDA-regulated drug study